161 related articles for article (PubMed ID: 37087978)
1. Iron deficiency in hepatocellular carcinoma cells induced sorafenib resistance by upregulating HIF-1α to inhibit apoptosis.
Gao Z; Wang D; Yang J; Li M; Ling C; Lv D; Cao Y; Chen Z; Shi C; Shen H; Tang Y
Biomed Pharmacother; 2023 Jul; 163():114750. PubMed ID: 37087978
[TBL] [Abstract][Full Text] [Related]
2. PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
Long Q; Zou X; Song Y; Duan Z; Liu L
Biochem Biophys Res Commun; 2019 Jun; 513(3):642-650. PubMed ID: 30981500
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
[TBL] [Abstract][Full Text] [Related]
6. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
[TBL] [Abstract][Full Text] [Related]
7. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
[TBL] [Abstract][Full Text] [Related]
8. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells.
Xu M; Zheng YL; Xie XY; Liang JY; Pan FS; Zheng SG; Lü MD
DNA Cell Biol; 2014 May; 33(5):275-81. PubMed ID: 24611881
[TBL] [Abstract][Full Text] [Related]
10. Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na
Jiang W; Li G; Li W; Wang P; Xiu P; Jiang X; Liu B; Sun X; Jiang H
Sci Rep; 2018 Jun; 8(1):9706. PubMed ID: 29946188
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
12. Combined Treatment of Tanshinone I and Epirubicin Revealed Enhanced Inhibition of Hepatocellular Carcinoma by Targeting PI3K/AKT/HIF-1α.
Zhao J; Lin E; Cai C; Zhang M; Li D; Cai S; Zeng G; Yin Z; Wang B; Li P; Hong X; Chen J; Zou B; Li J
Drug Des Devel Ther; 2022; 16():3197-3213. PubMed ID: 36158238
[TBL] [Abstract][Full Text] [Related]
13. Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy.
Zhou S; Liu Y; Zhang Q; Xu H; Fang Y; Chen X; Fu J; Yuan Y; Li Y; Yuan L; Xiang C
Stem Cell Res Ther; 2023 Apr; 14(1):58. PubMed ID: 37005657
[TBL] [Abstract][Full Text] [Related]
14. Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Hua L; Hu B; Yan D; Liu J; Shen Y; Zhao F; Shen C; Chen B; Cui X
Pathol Res Pract; 2017 Jun; 213(6):688-697. PubMed ID: 28476378
[TBL] [Abstract][Full Text] [Related]
15. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N
Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
Méndez-Blanco C; Fondevila F; García-Palomo A; González-Gallego J; Mauriz JL
Exp Mol Med; 2018 Oct; 50(10):1-9. PubMed ID: 30315182
[TBL] [Abstract][Full Text] [Related]
17. The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways.
Abd-Elbaset M; Mansour AM; Ahmed OM; Abo-Youssef AM
Naunyn Schmiedebergs Arch Pharmacol; 2020 Sep; 393(9):1611-1624. PubMed ID: 32270258
[TBL] [Abstract][Full Text] [Related]
18. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma.
Li X; Li Y; Lian P; Lv Q; Liu F
Hum Exp Toxicol; 2023; 42():9603271221142818. PubMed ID: 36786348
[TBL] [Abstract][Full Text] [Related]
19. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
[TBL] [Abstract][Full Text] [Related]
20. Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death.
Li S; Li J; Dai W; Zhang Q; Feng J; Wu L; Liu T; Yu Q; Xu S; Wang W; Lu X; Chen K; Xia Y; Lu J; Zhou Y; Fan X; Mo W; Xu L; Guo C
Br J Cancer; 2017 Nov; 117(10):1518-1528. PubMed ID: 28926527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
